Tojjari Alireza, Idrissi Yassine Alami, Saeed Anwaar
Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, 15213, USA.
Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, 15213, USA; UPMC Hillman Cancer Center, Pittsburgh, PA, 15213, USA.
Cancer Lett. 2024 Dec 3;611:217362. doi: 10.1016/j.canlet.2024.217362.
Recently, the molecular landscape of gastric and pancreatic cancers has advanced with Claudin 18.2 (CLDN18.2) emerging as a promising therapeutic target. Claudin 18.2, a tight junction protein, is selectively expressed in cancer cells and minimally in normal tissues, making it an attractive candidate for targeted therapy. Therapies like monoclonal antibodies (e.g., zolbetuximab), bispecific antibodies, and antibody-drug conjugates have shown significant potential in improving clinical outcomes. Early-phase clinical trials demonstrate robust antitumor activity, particularly in combination with chemotherapy and immunotherapy regimens. However, challenges such as patient selection, resistance mechanisms, and toxicity management remain critical. This review highlights the therapeutic landscape, clinical advancements, and future directions of targeting Claudin 18.2 in gastric and pancreatic cancer treatment.
最近，胃癌和胰腺癌的分子格局不断发展，Claudin 18.2（CLDN18.2）成为一个有前景的治疗靶点。Claudin 18.2是一种紧密连接蛋白，在癌细胞中选择性表达，在正常组织中表达极少，这使其成为靶向治疗的一个有吸引力的候选靶点。单克隆抗体（如zolbetuximab）、双特异性抗体和抗体药物偶联物等疗法在改善临床结果方面已显示出巨大潜力。早期临床试验证明了强大的抗肿瘤活性，特别是与化疗和免疫治疗方案联合使用时。然而，患者选择、耐药机制和毒性管理等挑战仍然至关重要。本综述重点介绍了在胃癌和胰腺癌治疗中靶向Claudin 18.2的治疗前景、临床进展和未来方向。
